340B Drug Discount Fight Moves To States As PhRMA Opposes Louisiana Law
PhRMA points to federal court rulings against HHS’s view that companies cannot limit discounts to contract pharmacies. However, there is a split among district courts and while one appellate court has sided with industry two have yet to issue opinions.
You may also be interested in...
Ranking Republican on Senate HELP Committee seeks detailed information on companies’ 340B operations, revenue sources and whether discounts are shared with patients.
Industry stakeholders have filed various lawsuits against the US government, attempting to slow down or block the implementation of a new Medicare drug price negotiation program. Pink Sheet's new chart tracks the developments.
Complaint seeks permanent injunction to require drug pricing program to give stakeholders opportunity to comment on the process and make decisions subject to judicial review.